Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: * Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. * Mesothelioma accounts for 0.10% of deaths annually in the United States. Malignant pleural mesothelioma is the most common of these, comprising of 80% of the cases with an annual incidence of about 2,500 in the United States. * The median survival from diagnosis of pleural mesothelioma is approximately 12 months. The majority of patients present with stage III or IV disease with 85-90% of patients considered unresectable at diagnosis. * Peritoneal mesothelioma has a better prognosis than pleural mesothelioma; nevertheless, patients undergoing therapy for peritoneal mesothelioma have few well-studied treatment options due in large part to the rarity of the disease. * In addition to mesothelioma, mesothelin is highly expressed in several cancers, including pancreatic, biliary adenocarcinomas, gastric and ovarian cancers; mesothelin is also expressed in a significantly larger proportion of thymic carcinoma than thymoma. Objectives: -To allow sample acquisition for use in the study of mesothelioma. Eligibility: * All participants age greater than or equal to 2 years with malignant mesothelioma OR * All participants greater than or equal to 18 years with thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers or other solid tumor known to express mesothelin * Must be able and willing to provide informed consent if 18 or over; parent or guardian must be able and willing to provide consent for patients under the age of 18 Design: * Up to 1000 subjects will be enrolled. * Patients will be followed to determine the course of disease and to record any treatment received for mesothelioma. * Patients will undergo sampling of blood, urine, tumor and abnormal body fluids for tissue banking. * Studies which may be performed on banked material include genetic and genomic studies, establishment of cell cultures and immunologic studies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 2 lat i starsze z rakiem międzybłoniakowym.
- •Osoby w wieku 18 lat i starsze z rakiem grasicy, trzustki, dróg żółciowych, płuc, żołądka, jajnika lub innymi guzami, o których wiadomo, że produkują specyficzne białko (mezotelina).
- •Potwierdzona diagnoza choroby przez badanie laboratoryjne.
- •Zgoda na udział w badaniu (lub zgoda rodzica/opiekuna dla osób poniżej 18 lat).
✗ Disqualifies
- •Ciężkie choroby narządów, które mogłyby zwiększyć ryzyko biopsji (np. choroba serca, problemy z płucami).
- •Kobiety w ciąży.
- •Aktywne choroby (fizyczne lub psychiczne), które mogą zwiększyć ryzyko dla uczestnika.
- •Osoby dorosłe, które nie mogą wyrazić świadomej zgody na udział.
Simplified criteria — AI translation
Trial details
- Minimum age
- 2 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Maria Gracia L Agra, R.N.
Raffit Hassan, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.